Zhuhai Rundu Pharmaceutical Co., Ltd. (SHE:002923)
China · Delayed Price · Currency is CNY 15.39
-0.31 (-1.97%)
Feb 4, 2026, 1:05 PM CST
SHE:002923 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,184 | 1,177 | 1,282 | 1,363 | 1,188 | 1,247 |
Other Revenue | 5.53 | 5.53 | 10.06 | 9.01 | 1.98 | 6.07 |
| 1,190 | 1,182 | 1,292 | 1,372 | 1,190 | 1,253 | |
Revenue Growth (YoY) | -2.76% | -8.48% | -5.85% | 15.32% | -5.01% | -7.89% |
Cost of Revenue | 771.62 | 691.9 | 685.03 | 636.32 | 478.84 | 491.79 |
Gross Profit | 418.15 | 490.47 | 606.86 | 735.92 | 711.09 | 760.84 |
Selling, General & Admin | 331.62 | 310.35 | 392.51 | 459.74 | 475.85 | 528.72 |
Research & Development | 102.92 | 129.2 | 127.3 | 92.34 | 84.27 | 93.69 |
Other Operating Expenses | 11.99 | 11.27 | 15.46 | 15.25 | 12 | -14.44 |
Operating Expenses | 451.96 | 450.95 | 535.43 | 569.89 | 572.6 | 607.28 |
Operating Income | -33.81 | 39.52 | 71.43 | 166.02 | 138.49 | 153.55 |
Interest Expense | -13.75 | -15.78 | -16.12 | -6.97 | -1.77 | -1.77 |
Interest & Investment Income | 1.53 | 1.33 | 2.25 | 1.48 | 2.33 | 6.13 |
Currency Exchange Gain (Loss) | 2.85 | 2.85 | 1.76 | 1.3 | -1.34 | -3.03 |
Other Non Operating Income (Expenses) | -3.26 | -1.94 | -0.4 | -0.45 | -0.86 | -3.77 |
EBT Excluding Unusual Items | -46.44 | 25.98 | 58.92 | 161.38 | 136.84 | 151.11 |
Gain (Loss) on Sale of Investments | -0 | 0.01 | -0.36 | -0.02 | -0.02 | 0.01 |
Gain (Loss) on Sale of Assets | 17.98 | 18.02 | 27.58 | 0.05 | - | - |
Asset Writedown | -19.85 | -0.43 | -0.18 | -0.33 | -0.23 | -2.29 |
Other Unusual Items | -3.19 | -0.96 | 0.09 | 19.86 | 15.14 | - |
Pretax Income | -51.49 | 42.63 | 86.04 | 180.94 | 151.74 | 148.83 |
Income Tax Expense | 0.49 | 2.74 | 19.14 | 25.46 | 11.97 | 12.97 |
Net Income | -51.99 | 39.88 | 66.9 | 155.48 | 139.77 | 135.86 |
Net Income to Common | -51.99 | 39.88 | 66.9 | 155.48 | 139.77 | 135.86 |
Net Income Growth | - | -40.38% | -56.97% | 11.24% | 2.87% | 14.27% |
Shares Outstanding (Basic) | 335 | 332 | 334 | 338 | 337 | 334 |
Shares Outstanding (Diluted) | 335 | 332 | 334 | 338 | 337 | 334 |
Shares Change (YoY) | -2.03% | -0.64% | -1.04% | 0.19% | 0.96% | -1.19% |
EPS (Basic) | -0.16 | 0.12 | 0.20 | 0.46 | 0.41 | 0.41 |
EPS (Diluted) | -0.16 | 0.12 | 0.20 | 0.46 | 0.41 | 0.41 |
EPS Growth | - | -40.00% | -56.52% | 11.03% | 1.89% | 15.64% |
Free Cash Flow | 70.36 | 129.94 | -1.85 | -116.75 | -170.58 | -6.4 |
Free Cash Flow Per Share | 0.21 | 0.39 | -0.01 | -0.34 | -0.51 | -0.02 |
Dividend Per Share | 0.150 | 0.150 | 0.200 | 0.250 | 0.220 | 0.220 |
Dividend Growth | -25.00% | -25.00% | -20.00% | 13.74% | - | - |
Gross Margin | 35.14% | 41.48% | 46.98% | 53.63% | 59.76% | 60.74% |
Operating Margin | -2.84% | 3.34% | 5.53% | 12.10% | 11.64% | 12.26% |
Profit Margin | -4.37% | 3.37% | 5.18% | 11.33% | 11.75% | 10.85% |
Free Cash Flow Margin | 5.91% | 10.99% | -0.14% | -8.51% | -14.34% | -0.51% |
EBITDA | 117.17 | 173.31 | 182.29 | 235.45 | 198.39 | 203.53 |
EBITDA Margin | 9.85% | 14.66% | 14.11% | 17.16% | 16.67% | 16.25% |
D&A For EBITDA | 150.98 | 133.79 | 110.86 | 69.43 | 59.91 | 49.98 |
EBIT | -33.81 | 39.52 | 71.43 | 166.02 | 138.49 | 153.55 |
EBIT Margin | -2.84% | 3.34% | 5.53% | 12.10% | 11.64% | 12.26% |
Effective Tax Rate | - | 6.44% | 22.25% | 14.07% | 7.89% | 8.71% |
Revenue as Reported | 1,190 | 1,182 | 1,292 | 1,372 | 1,190 | 1,253 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.